RCP
AERI

Rothschild Capital Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Rothschild Capital Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,000
Closed -$180K – 44
2013
Q4 		$180K Buy
+10,000
New +$130K 0.08% 39

Other funds holding AERI

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Rothschild Capital Partners's AERI Position: Q1 2014 in Review

Rothschild Capital Partners sold out of Aerie Pharmaceuticals (AERI) in Q1 2014, closing a stake of 10,000 shares — an estimated $180K sold.

Rothschild Capital Partners first reported a position in AERI in Q4 2013 and held it in 1 quarter. The position peaked at $180K in Q4 2013. 53 funds tracked by Wall St. Rank hold AERI as of Q1 2014.

  • Rothschild Capital Partners reported no remaining Aerie Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Rothschild Capital Partners sold 10,000 Aerie Pharmaceuticals shares in Q1 2014, an estimated $180K.
  • Rothschild Capital Partners first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Rothschild Capital Partners's Aerie Pharmaceuticals position peaked at $180K in Q4 2013.
  • 53 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2014.

Based on Rothschild Capital Partners's 13F filing for Q1 2014, filed 12 May 2014.